These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21495689)

  • 1. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity.
    Banala AK; Levy BA; Khatri SS; Furman CA; Roof RA; Mishra Y; Griffin SA; Sibley DR; Luedtke RR; Newman AH
    J Med Chem; 2011 May; 54(10):3581-94. PubMed ID: 21495689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands.
    Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH
    Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
    Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR
    J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents.
    Grundt P; Prevatt KM; Cao J; Taylor M; Floresca CZ; Choi JK; Jenkins BG; Luedtke RR; Newman AH
    J Med Chem; 2007 Aug; 50(17):4135-46. PubMed ID: 17672446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.
    Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L
    J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands.
    Cao Y; Min C; Acharya S; Kim KM; Cheon SH
    Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
    Leopoldo M; Lacivita E; Colabufo NA; Contino M; Berardi F; Perrone R
    J Med Chem; 2005 Dec; 48(25):7919-22. PubMed ID: 16335915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.
    Newman AH; Grundt P; Cyriac G; Deschamps JR; Taylor M; Kumar R; Ho D; Luedtke RR
    J Med Chem; 2009 Apr; 52(8):2559-70. PubMed ID: 19331412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands.
    Zhou B; Hong KH; Ji M; Cai J
    Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-affinity relationship study on N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamides as potent and selective dopamine D(3) receptor ligands.
    Leopoldo M; Berardi F; Colabufo NA; De Giorgio P; Lacivita E; Perrone R; Tortorella V
    J Med Chem; 2002 Dec; 45(26):5727-35. PubMed ID: 12477356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of the dopamine D3 receptor. Part II.
    Leopoldo M; Lacivita E; De Giorgio P; Contino M; Berardi F; Perrone R
    Bioorg Med Chem; 2009 Jan; 17(2):758-66. PubMed ID: 19081257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor.
    Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM
    Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatic linker variations in novel dopamine D
    Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D
    Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH
    Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using click chemistry toward novel 1,2,3-triazole-linked dopamine D3 receptor ligands.
    Keck TM; Banala AK; Slack RD; Burzynski C; Bonifazi A; Okunola-Bakare OM; Moore M; Deschamps JR; Rais R; Slusher BS; Newman AH
    Bioorg Med Chem; 2015 Jul; 23(14):4000-12. PubMed ID: 25650314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of N-phenyl homopiperazine analogs as potential dopamine D3 receptor selective ligands.
    Li A; Mishra Y; Malik M; Wang Q; Li S; Taylor M; Reichert DE; Luedtke RR; Mach RH
    Bioorg Med Chem; 2013 Jun; 21(11):2988-98. PubMed ID: 23618707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.